| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 2.1 | 2.1 | 2.3 |
| Total income | 2.1 | 2.1 | 2.3 |
| Profit before exceptional items & tax | -0.5 | -0.0 | 0.1 |
| Exceptional items | 0.3 | 0.3 | 0.1 |
| Profit before tax | -0.2 | 0.3 | 0.2 |
| Net profit | -0.1 | 0.2 | 0.3 |
| Operating margin | -9.5% | 14.3% | 8.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -8.70% |
|---|
BSE results filing, BSE: 541299. Figures extracted from the filing.
Dr. Lalchandani Labs Ltd: key numbers
- Share price
- ₹6.55
- Market cap
- ₹5.68 Cr
- Revenue (annual)
- ₹4.19 Cr
- Net profit (annual)
- ₹0.06 Cr
- P/E (TTM)
- 89.2×Sector 53.1×
- Promoter holding
- 32.90%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lalchandani Labs Ltd
All →Dr. Lalchandani Labs Other Announcement
Dr Lalchandani Labs Ltd. received an extension from the Registrar of Companies to hold its AGM for FY 2025-26 by December 31, 2026.
Dr. Lalchandani Labs Board Meeting Date
Dr Lalchandani Labs Limited postponed its May 30 board meeting to June 03, 2026. The delay allows for internal review of financial data before results approval.
Dr. Lalchandani Labs Capacity Expansion: ₹1 Cr Investment
Dr Lalchandani Labs opened a new strategic centre in Dwarka, Delhi. The facility targets a ₹1 Crore annual revenue contribution from local government employee residents.
- Value
- ₹1.00 Cr
Dr. Lalchandani Labs Board Meeting Date
Dr Lalchandani Labs scheduled a board meeting on May 30, 2026, to approve annual audited financial results. The trading window remains closed until June 1.
Dr. Lalchandani Labs Other Announcement
Dr Lalchandani Labs Ltd confirmed it does not meet the 'Large Corporate' criteria for FY 2025-26 under SEBI debt-raising norms. The company reported zero incremental borrowings and no mandatory debt-sourcing requirements as its long-term borrowings remain below the Rs. 1000 crore threshold.
Dr. Lalchandani Labs Debt & Borrowing
Dr Lalchandani Labs Ltd confirmed it does not qualify as a Large Corporate entity for the financial year 2026. The company reported zero outstanding borrowings as of March 31, 2026, and is therefore not subject to SEBI's mandatory debt-raising framework for large entities.